Search Results
Phase 2 Trial of Selinexor Shows Durable Responses in DLBCL
The SADAL study: selinexor for R/R DLBCL
Update on selinexor for myeloma and large cell lymphomas
Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Selinexor, selective inhibitor of nuclear export, for non-Hodgkin lymphoma
Key novel agents for relapsed diffuse large B-cell lymphoma
The Next Phase of Targeted Therapy in MCL and DLBCL
Perspectives on Novel Antibody Platforms in DLBCL
Selinexor for RRMM
Ibrutinib resistance-mechanisms and options in CLL
BOSTON Study; SVd in Relapsed/Refractory Multiple Myeloma
Emerging Therapies in Myeloma: Selinexor
